The impact of single agent PD-1 or PD-L1 inhibition on advanced endometrial cancers: meta-analysis

BACKGROUND: Immune checkpoint inhibitor (ICI) therapy is an emerging option for advanced endometrial cancer (EC). Mismatch repair (MMR) status is widely regarded as a biomarker predictive of response to ICIs. The predictive value of MMR based on small, single-arm trials, however, is conflicting. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Kok, P.-S., Antill, Y.C., Scott, C.L., Lee, C.K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808459/
https://www.ncbi.nlm.nih.gov/pubmed/36410086
http://dx.doi.org/10.1016/j.esmoop.2022.100635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808459/
https://www.ncbi.nlm.nih.gov/pubmed/36410086
http://dx.doi.org/10.1016/j.esmoop.2022.100635

Ejemplares similares